ArticleLife (Basel, Switzerland)2026
Albumin-Based Indices and Hematologic Ratios as Predictors of Short-Term Response to Anti-TNF Therapy in Crohn's Disease: A Single-Center Retrospective Study.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Biological agents such as infliximab [IFX] and adalimumab [ADA] are employed in the treatment of severe Crohn's disease [CD], especially in cases refractory to conventional therapies. This study assessed the predictive value of simple serum-based markers in terms of early response to anti-tumor necrosis factor [anti-TNF] biologics.
methodsA total of 55 adult patients who had undergone 57 individual courses of either IFX or ADA at the Department of Gastroenterology of the Medical University of Łódź were retrospectively evaluated: 33 males and 22 females, aged 18-70 years. Serum parameters were assessed upon initiation of biological therapy and at the 14th week treatment response assessment juncture.
resultsA total of 50 of the 57 (87.7%) assessed courses presented with treatment response upon week 14. Intergroup comparison revealed a statistically significant discrepancy in albumin concentration between the responder and non-responder groups: 38.4 g/L (35-41) vs. 28.4 g/L (26.7-30.1) (
conclusionsSimple, readily available serum-derived markers appear promising in assessing the likelihood of early anti-TNF response in CD patients. Albumin and albumin-derived parameters especially demonstrated considerable potential in this regard.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.